Meanwhile, the BSE Sensex was down 2.70 points, or 0.01% to 18,235.61 On BSE, 73,365 shares were traded in the counter as against an average daily volume of 28,722 shares in the past one quarter. The stock hit a high of Rs 369.10 and a low of Rs 360.35 so far during the day. The stock had hit a record high of Rs 397 on 28 July 2010 and a 52-week low of Rs 190 on 3 September 2009. The large-cap stock underperformed the market over the past one month till 2 September 2010, falling 5.26% as compared to the Sensex's 0.87% rise. It had also underperformed the market in the past one quarter, declining 2.25% as compared to the Sensex's return of 8.94%. The company's equity capital is Rs 89.11 crore. Face value per share is Rs 2. The US Food and Drug Administration (US FDA) has reportedly given permission to Lupin to seek approval for a generic version of Lipitor with a different formulation than the original drug. Lupin must go through the normal generic-drug approval process before it can launch its proposed capsule version of Lipitor. The original Lipitor is the top-selling prescription drug in the world, with $11.4 billion in global sales last year and $5.7 billion in the US alone. Lupin's consolidated net profit jumped 40.10% to Rs 196.30 crore on 20.90% increase in net sales to Rs 1312.09 crore in Q1 June 2010 over Q1 June 2009. Powered by Capital Market - Live News |